Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 8:51 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.9% | 1,512,483 (+52.38%) | View |
| 2024-02-14 5:01 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | RA CAPITAL MANAGEMENT L.P. | 4,163,211 9.7% | 1,373,490 (+49.23%) | View |
| 2024-02-14 4:37 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Kirn David | 2,033,069 4.7% | 10,571 (+0.52%) | View |
| 2024-02-14 09:56 am Unchanged | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.4% | 0 (Unchanged) | View |
| 2024-02-14 08:43 am Sale | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Deep Track Capital LP | 2,284,372 5.34% | -372,529 (-14.02%) | View |
| 2024-02-13 10:56 am Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | JANUS HENDERSON GROUP PLC JHG | 3,093,296 7.2% | 1,627,029 (+110.96%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BlackRock Inc. BLK | 3,464,587 8.1% | 955,955 (+38.11%) | View |
| 2024-01-08 4:15 pm Sale | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | VIKING GLOBAL INVESTORS LP | 4,247,914 9.9% | -540,000 (-11.28%) | View |
| 2024-01-08 4:05 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | VIKING GLOBAL INVESTORS LP | 4,787,914 11.2% | 850,000 (+21.59%) | View |
| 2023-06-05 4:31 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | RA CAPITAL MANAGEMENT L.P. | 2,789,721 6.7% | 2,789,721 (New Position) | View |
| 2023-05-15 4:17 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Venrock Healthcare Capital Partners III L.P. | 2,887,517 8.7% | 2,887,517 (New Position) | View |
| 2023-02-14 08:32 am Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Deep Track Capital LP | 2,656,901 8.2% | 756,901 (+39.84%) | View |
| 2023-02-09 09:07 am Sale | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | JANUS HENDERSON GROUP PLC JHG | 1,466,267 4.5% | -181,656 (-11.02%) | View |
| 2023-02-08 4:15 pm Sale | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Kirn David | 2,022,498 6.2% | -11,877 (-0.58%) | View |
| 2023-01-31 1:58 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BlackRock Inc. BLK | 2,508,632 7.7% | 420,950 (+20.16%) | View |
| 2022-06-21 4:53 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 12.4% | 2,001,551 (+99.79%) | View |
| 2022-02-14 5:02 pm Unchanged | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | VIKING GLOBAL INVESTORS LP | 3,937,914 12.3% | 0 (Unchanged) | View |
| 2022-02-14 4:33 pm Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Kirn David | 2,034,375 6.3% | 34,375 (+1.72%) | View |
| 2022-02-14 4:32 pm Sale | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | SCHAFFER DAVID | 901,215 2.8% | -1,098,785 (-54.94%) | View |
| 2022-02-14 08:56 am Purchase | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | Deep Track Capital LP | 1,900,000 5.91% | 100,000 (+5.56%) | View |